SELANK

Selank is a synthetic heptapeptide (7 amino acids) designed to influence the central nervous system and immune system. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and has been researched primarily as a potential anxiolytic (anti-anxiety) compound.

Unlike many anxiety medications, Selank does not appear to act as a sedative and is being investigated for its ability to regulate neurotransmitters without strong dependency risk.

Mechanism of Action

Selank appears to influence several brain signaling systems:

1. GABA modulation

• Enhances signaling of GABA, the brain’s primary calming neurotransmitter.

• Similar pathway to benzodiazepines but without the same receptor binding.

2. Dopamine & serotonin regulation

• May normalize dopamine and serotonin signaling.

• Linked to improvements in mood and mental clarity.

3. BDNF expression

• Research suggests increased Brain-Derived Neurotrophic Factor (BDNF).

• BDNF supports neuroplasticity, learning, and memory formation.

4. Immune modulation

• Derived from tuftsin, which interacts with immune cells.

• May influence cytokine signaling.

Potential Benefits Being Studied

Research and user reports commonly focus on the following potential effects:

Anxiety Reduction

Selank is primarily researched as a non-sedating anxiolytic.

Possible effects include:

• Reduced generalized anxiety

• Less stress response

• Emotional stabilization

Cognitive Support

Studies have explored possible improvements in:

• Memory formation

• Mental clarity

• Focus

• Learning capacity

Mood Regulation

Some research suggests Selank may help stabilize mood without strong stimulant effects.

Immune Signaling Support

Because of its tuftsin origin, Selank may interact with immune pathways involved in inflammation regulation.

Administration

Selank is commonly administered intranasally because peptides can reach the brain through the olfactory pathway.

Typical research dosing protocols often explore:

• 250–400 mcg per dose

• 1–3 times per day

Cycles commonly studied:

• 10–14 days

• Some protocols extend to 30 days

Pharmacokinetics

• Rapid absorption via nasal mucosa

• Peak CNS effects often reported within 30–60 minutes

• Short half-life, but downstream neurochemical effects may persist longer

Differences From Similar Peptides

Selank and Semax are often discussed together because both are Russian-developed nootropic peptides used intranasally.

Safety Profile (Research Context)

Studies generally report:

• Low toxicity

• No significant withdrawal effects

• No strong sedative action

• Minimal impact on blood pressure

However, long-term human data is still limited outside Russian clinical studies.

Important Notes

• Selank is not FDA-approved for medical use in the United States.

• Most research exists in Russian clinical literature.

• Individual responses may vary.